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Abstract
Background: Human cyclin A2 is a key regulator of S phase progression and entry into mitosis. Alternative splice variants of
the G1 and mitotic cyclins have been shown to interfere with full-length cyclin functions to modulate cell cycle progression
and are therefore likely to play a role in differentiation or oncogenesis. The alternative splicing of human cyclin A2 has not
yet been studied.
Methodology/Principal Findings: Sequence-specific primers were designed to amplify various exon–intron regions of
cyclin A2 mRNA in cell lines and human tissues. Intron retaining PCR products were cloned and sequenced and then
overexpressed in HeLa cells. The subcellular localization of the splice variants was studied using confocal and time-lapse
microscopy, and their impact on the cell cycle by flow cytometry, immunoblotting and histone H1 kinase activity. We found
a splice variant of cyclin A2 mRNA called A2V6 that partly retains Intron 6. The gene expression pattern of A2V6 mRNA in
human tissues was noticeably different from that of wild-type cyclin A2 (A2WT) mRNA. It was lower in proliferating fetal
tissues and stronger in some differentiated adult tissues, especially, heart. In transfected HeLa cells, A2V6 localized
exclusively in the cytoplasm whereas A2WT accumulated in the nucleus. We show that A2V6 induced a clear G1/S cell cycle
arrest associated with a p21 and p27 upregulation and an inhibition of retinoblastoma protein phosphorylation. Like A2WT,
A2V6 bound CDK2, but the A2V6/CDK2 complex did not phosphorylate histone H1.
Conclusion/Significance: This study has revealed that some highly differentiated human tissues express an intron-retaining
cyclin A2 mRNA that induced a G1/S block in vitro. Contrary to full-length cyclin A2, which regulates cell proliferation, the
A2V6 splice variant might play a role in regulating nondividing cell states such as terminal differentiation or senescence.
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Introduction
Cyclins play an essential role in progression through the
eukaryotic cell cycle, acting as regulatory subunits of cyclin-
dependent kinases (CDKs). Types A and B cyclins are more
specifically responsible for the onset of mitosis, and through their
degradation, the exit from mitosis. Their activities are determined
by changes in their subcellular localization during successive
phases of the cell cycle [1].
Cyclin A2 achieves its regulatory activity predominantly, if not
exclusively, in the nucleus from the G1/S transition to mitosis,
participating in the entry into, and progress through, S phase,
DNA replication, centrosome duplication, and the entry into
mitosis [2–4]. The existence of cytoplasmic cyclin A2 in the
physiologic situation has long been controversial. However, several
reports have described the presence of cyclin A2 within the
cytoplasm during the S phase [5], [6] and within the centrosome
during mitosis [7], [8]. Cyclin A/CDK2 complexes have been
found in the microsomal and endocytic compartments of
regenerative liver cells [9–11]. It has previously been reported
that endoplasmic reticulum-associated non-degraded cyclin A2
was able to interact with, and activate, CDKs [12] and had the
ability to transform in vivo and in vitro [13]. Traffic of cyclin A2/
CDK2 complexes between the nucleus and cytoplasm is a dynamic
process [14], and an isoform of cyclin A2 exists in the cytoplasm
[15], [16]. The biological role of cytoplasmic cyclin A2 remains to
be elucidated.
Alternative splicing can generate multiple transcripts encoding
proteins with subtle or opposing functional differences that can
have profound biological consequences [17]. Many alternative
splicing events occur only in a specific tissue at a specific time
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[17]. Previous estimates, based on analysis of expressed sequence
tags (EST), suggest that the transcripts from 35% of human genes
are alternatively spliced [18], [19]. Several forms of cyclin E
mRNA were detected and cloned [20], [21]. Some were expressed
in tumor tissues and not in non-tumor tissues [22], [23], and
revealed alternate substrate affinity [24]. A splice variant of cyclin
D1 encodes a protein with an altered C-terminal domain and has
been detected in a range of cell lines and tissues. It is localized
constitutively in the nucleus and is a potent oncogenic agent [25].
Lozano et al. reported a splice variant of cyclin B with retention of
an intronic sequence, which was first discovered in a sea urchin
and observed to be abundant in the oocyte of the embryo [26].
This variant differs from wild-type cyclin B in the structure of the
C-terminal and may be involved in the control of cell division and
differentiation. The same group subsequently reported the
existence of splicing variants of human cyclin B3 [27].
Based on the homology of the C-terminal sequences of cyclins B
and A, we hypothesized the existence of splice variants of cyclin
A2. In this study, we identified and analyzed a splice variant of
cyclin A2, termed A2V6, which retains Intron 6. A2V6 is highly
expressed in adult tissues such as the heart, liver, and kidney but is
not expressed in the same tissues in the fetus. We demonstrated
that A2V6 was localized exclusively in the cytoplasm of transfected
HeLa cells. Furthermore, it induced the G1/S cell-cycle block and
bound CDK2 without stimulating its histone H1-kinase activity.
This suggests that A2V6 may play a role in the regulation of
cellular differentiation.
Results
An Intron-retaining Cyclin A2 Splice Variant is Expressed
in Human Tissues
B-type cyclins are subject to an alternative splicing that gives
rise to C-terminus intron retention [26]. Knowing that A- and B-
type cyclins have large regions of homology in their C terminus,
we sought intron-retaining splice variants of cyclin A2 in human
adult and fetal tissues. The human cyclin A2 gene is organized in
8 exons displaying canonical intron/exon and exon/intron
borders (Fig. 1A). The length of the mature cyclin A2 (A2WT)
mRNA is of 2.5 kb. Using sequence-specific primers designed to
amplify exon–intron regions, we were able to amplify a 1.3 kb
cDNA in some human tissues (brain, kidney, muscle, heart,
spleen, liver), which was showed by sequencing to comprise the
first six exons and a retained portion (GTATGTAT-
TACGGTCTTCACACACCTATCTTGTGAC) of Intron 6 of
cyclin A2 (Fig. 1A and B). Gene-expression analysis by PCR-
Southern blotting revealed preferentially the 2.5 kb A2WT
mRNA in highly proliferating fetal and placental tissues
(Fig. 1B), consistent with A2WT being a S phase cyclin [28],
[29]. It is interesting to note that the expression of A2V6 mRNA
was noticeably lower than that of A2WT mRNA in the
proliferating fetal tissues. In contrast, A2V6 mRNA was more
strongly detected than A2WT mRNA in some differentiated
adult tissues, namely, the brain, kidney, muscle, and, especially,
heart. It should be noted that fetal kidney displayed a signal of
higher molecular weight (1.5 kb) than A2V6 mRNA. This signal
was found, by sequencing, to correspond to an mRNA splice
variant containing Exons 1 to 6 and Introns 5 and 6. These
observations establish the existence of a tissue-specific alternative
splicing of the mRNA of cyclin A2, and suggest a link between
cyclin A2 alternative splicing and tissue differentiation.
Cyclin A2V6 Variant Protein is Sequestered in the
Cytoplasm During the Cell Cycle
To gain insight into the biological role of cyclin A2 splice
variants, we investigated the subcellular localization of the A2WT-
GFP and A2V6-GFP fusion proteins in HeLa cells. We used GFP
tags to trace those cells, which overexpress the corresponding
constructs, and an anti-cyclin A2 antibody, which recognizes
endogenous cyclin A2, exogenous A2WT-GFP, and, with a lesser
efficacy, exogenous A2V6-GFP. A hundred of cells transfected by
each construct were examined. We found that the A2V6-GFP
fusion protein localized exclusively in the cytoplasm of transfected
cells, contrary to A2WT-GFP, which was predominantly located
in the nucleus (Fig. 2A). Anti-cyclin A2 immunodetection showed
that all the examined A2WT-GFP transfected cells had a nuclear
cyclin A2 staining. About 20% of the non-transfected cells
displayed such a staining. None of the hundred A2V6-GFP
transfected cells studied displayed any nuclear endogenous cyclin
A2, suggesting that these cells do not undergo S phase. Staining
with specific organelle markers showed that A2V6-GFP did not
localize in early or late endosomes, Golgi apparatus, or the
Figure 1. Distribution of the A2V6 splice variant of cyclin A2 in
human tissues. (A) Exon-Intron organization of the Human cyclin A2
gene. Black boxes: exons. Grey boxes: 59 and 39 UTR. D-box: destruction
box. MRAIL: CDK2 binding motif belonging to the cyclin box. Cyclin A2:
gene. A2WT: mature cyclin A2 messenger resulting from alternate RNA
splicing and amplified using the X1S-E8B primer pair. A2V6: cyclin A2
splice variant mRNA retaining a portion of Intron 6 (empty box)
amplified using the X1S-A2I6 primer pair. The indicated sequence
comprises the last nine nucleotides of Exon 6 (uppercase letters) and
the retained Intron 6 sequence (lowercase letters). (B) Gene-expression
analysis of cyclin A2 using PCR-Southern blotting in human adult and
fetal tissue samples from the indicated organs. A2WT: wild-type cyclin
A2 mRNA (2.5 kb). The 3.3 kb PCR product was determined to be A2WT
plus Intron-1 by sequencing. A2V6: cyclin A2 splice variant (1.3 kb).
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase (loading control).
doi:10.1371/journal.pone.0039249.g001
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A2WT-GFP and A2V6-GFP was followed in mitotic and daughter
transfected HeLa cells by time-lapse imaging. Figure 2B shows
that A2WT-GFP was concentrated in the nuclei in S/G2,
degraded during mitosis (time point 0 h), re-detected in the
daughter cells during G1 (2.7 h), and finally translocated again
into the nuclei (4 h and 11.5 h), which is similar to the behavior of
endogenous cyclin A2 [30], [31]. In contrast, A2V6-GFP
remained accumulated in the cytoplasm of transfected cells during
the whole cell cycle. Notably, A2V6-GFP was not translocated to
the nuclei in S Phase. Therefore, the A2V6-GFP expressing cells
did not progress through the cell cycle and rested in G1 until
apoptosis.
Cyclin A2v6 Splice Variant Induces G1/S Cell Cycle Arrest
We investigated the effect of the A2V6 splice variant on the
cell cycle by FACS analysis of HeLa cells synchronized at the
G1/S border using double thymidine block. The expression
levels of A2V6-GFP were similar to those of A2WT-GFP in
asynchronous and synchronized cell cultures, as revealed by anti-
GFP immunoblotting (Fig. 3A). FACS analysis of asynchronous
cell cultures revealed a substantial difference in cell cycle
distribution between A2V6- and A2WT-GFP-expressing cells,
Figure 2. Cytoplasmic localization of A2V6-GFP during the cell cycle. HeLa cells were transfected with wild-type cyclin A2-GFP (A2WT-GFP)
or Intron 6-retaining cyclin A2-GFP (A2V6-GFP) vectors. (A) Immunofluorescence images of transfected HeLa cells using anti-GFP (green) and anti-
cyclin A2 (red) antibodies. Nuclei (blue) were counterstained with Hoechst dye 33258. The A2V6-GFP protein is located in the cytoplasm of
transfected cells. No endogenous cyclin A2 is detected in cells expressing the A2V6 protein. (B) Time-lapse imaging of A2WT- and A2V6-GFP during
a cell cycle. Upper panel: Phase contrast microscopy. Lower panel: Fluorescence microscopy. Arrow: parent cell. Labels 1 and 2: daughter cells. Wild-
type cyclin A2-GFP is accumulated in G2 nuclei (21.3 h), degraded in mitosis and reappears mostly in the nuclei in S phase, like endogenous cyclin
A2. In contrast, A2V6-GFP remains in the cytoplasm throughout the cell cycle. Scale bar: 20 mm.
doi:10.1371/journal.pone.0039249.g002
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cell cycle progression (Fig. 3B). Thymidine synchronization
allowed us to compare the activities of the two fusion proteins
in S entry and progression. A2WT-GFP-expressing cells had
moved from G1/S to the S phase by 5.5 h after thymidine
removal (Th5.5) and a large proportion of them had completed
a cell cycle at Th10. In contrast, most (7662%) of the A2V6-
GFP-expressing cells were not capable of progressing through the
cell cycle and rested in G1/S up to Th10 (Fig. 3B). Next, to gain
insight into the biochemical underpinnings of prevention of the
G1/S transition, we investigated the expression of ectopic and
endogenous cyclin A2 in cells transfected with A2WT-GFP and
A2V6-GFP constructs. Anti-cyclin A2 immunoblots showed that
endogenous cyclin A2 was hardly expressed in A2V6-GFP-
transfected cells, whereas its expression level was strongly
increased in A2WT-GFP-transfected cells 5.5 h after thymidine-
block release (Fig. 3C). This is consistent with the G1/S arrest of
A2V6-GFP-transfected cells and the noticeable progress into S
phase of A2WT-GFP-transfected cells observed by flow cytome-
try upon release from the thymidine block. It is known that the
negative regulators of the cell cycle p21 and p27 are down-
regulated during the G1 to S-phase progression allowing the
cyclin A2-associated kinase activity to be deployed [32], [33]. We
found that both p21 and p27 were indeed suppressed in A2WT-
GFP-transfected cells at Th5.5, but were on the contrary
accumulated in A2V6-GFP-expressing cells, in agreement with
the cell cycle arrest that we have found in these cells (Fig. 3D).
We also know that the progression of cells into S phase is
associated with the hyperphosphorylation of the Retinoblastoma
protein (Rb) releasing the E2F transcription factor, which in turn
transactivates proliferative genes [34–37]. Immunoblotting for
phospho-Rb displayed the hyperphosphorylated form of Rb in
total cell lysates from A2WT-GFP-transfected cells, but not those
from A2V6-GFP-expressing cells (Fig. 3E).
The Cyclin A2V6 Splice Variant Forms an Inactive
Complex with CDK2
Cyclin A2 is known to form complexes with the protein kinase
CDK2 and thereby phosphorylate key substrates to promote S
phase and DNA replication [38]. Anti-CDK2 immunoprecipita-
tion followed by anti-GFP immunoblotting in lysates from
asynchronous A2WT- and A2V6-GFP-transfected cells showed
bands at about 85 and 75 kDa, respectively, corresponding to the
molecular size of the fusion proteins. This showed that the binding
efficiency of the A2V6 variant protein to CDK2 is comparable to
that of A2WT (Fig. 4A). Histone H1 kinase assays revealed that
the A2V6/CDK2 complex, contrary to A2WT/CDK2, did not
phosphorylate histone H1 in vitro (Fig. 4B).
Discussion
Evidence concerning the role of cyclins D and E in human
carcinogenesis has accumulated [39], [40]. In contrast, no
evidence of the transforming capacity of cyclin A2 has yet been
provided. However, a previous study based on an HBV-cyclin A2
fusion protein suggested a new mechanism of cyclin-related cell
transformation [41]. Furthermore, it has been demonstrated that
an endoplasmic reticulum (ER)-associated cyclin A2 mutant
triggers CDK activation [12], over-duplicates centrosome, in-
creases ploidy, and transforms cells [13]. These findings suggested
that the truncated forms of cyclin A2 has a different behaviour
from that of full-length cyclin A2, and is perhaps involved in cell
transformation.
This study has demonstrated the presence of an intron-
retaining cyclin A2 mRNA in some highly differentiated human
tissues, such as the heart, liver, and kidney. Its expression in
adult heart tissue was particularly marked. Cyclin A2 is generally
found in proliferating somatic tissues and is normally silenced in
the heart shortly after birth when cardiomyocyte division ceases
[42], [43]. Our findings suggest a role for the A2V6 splice
variant mRNA in cell differentiation through regulation of G1
phase.
This study emphasizes the existence of an endogenous A2V6
mRNA in human cells. Even though specific antibodies were
raised against the peptide specific of the retained intronic
sequence, no endogenous A2V6 protein could be detected. We
therefore overexpressed A2V6 protein in HeLa cells and studied
its subcellular localization during the cell cycle, and its effect on
cell-cycle progression.
Cyclin A2 is localized predominantly within the nucleus [15].
The synthesis of cyclin A2 is initiated in the late G1 phase, and
a degradation of cyclin A2 protein by the anaphase-promoting
complex (APC) occurs during prophase [3]. Interestingly, we
found that A2V6 was localized exclusively in the cytoplasm and
thereby had a critical effect on cell-cycle progression. An
overexpressed cytoplasmic A2V6 splice variant induced a long-
duration G1/S arrest following thymidine-block release, which
could lead to cell apoptosis. Cytoplasmic localization of
endogenous cyclin A2 has long been controversial. It has been
reported that a N-terminal-truncated cyclin A isoform was
localized in the cytoplasm and bound CDK2, suggesting that the
nuclear localization signal (NLS) of cyclin A2 is located in its N-
terminal part [44]. There are reports of N-terminal-truncated
mutants of cyclin A2 without destruction box (D-box) that were
located in the cytoplasm, escaped degradation and possessed
transforming activity [13], [41]. In this study, the A2V6 splice
variant contains the N-terminal part upstream of Exon 6, which
includes NLS and D-box, and lacks the C-terminal part
downstream of Exon 7. The fact that, nevertheless, A2V6 was
non-degraded until apoptosis could be a direct consequence of
the G1/S cell-cycle block.
Importantly, FACS analysis revealed that A2V6 has an
inhibitory effect on G1/S transition as a result of its sequestration
in the cytoplasm. Prevention of the G1/S transition related to
A2V6 was associated with an upregulation of p21 and p27 and an
absence of the hyperphosphorylated form of Rb, which suppressed
the expression of endogenous cyclin A2 and therefore hindered
cell cycle progression. This could be due to A2V6 occupying the
CDK2 binding site as an agonist and thus competing with A2WT.
Finally, the complex that was formed by A2V6 and CDK2 did not
induce histone H1 kinase activity. This suggests that the C-
terminal-truncated A2V6 is rendered kinase defective by some
conformational change, while the N-terminal part, which includes
the binding CDK domain, remains able to interact with CDK2
[45]. Additionally, it should be noted that unknown cytoplasmic
substrates might be phosphorylated by A2V6-associated kinase,
which would give a molecular basis to the G1/S arrest induced by
A2V6.
In conclusion, we have identified a cyclin A2 splice variant
mRNA with intronic retention called A2V6 that is preferentially
expressed in some human adult tissues and have demonstrated
a G1/S arrest in A2V6-transfected HeLa cells. This suggests that
endogenous A2V6 may play a role in the regulation of irreversible
nondividing cell states such as terminal differentiation or
senescence. Moreover, the fact that A2V6 induces cell growth
arrest and apoptosis designates this molecule as a potential
A Cyclin A2 Splice Variant Induces a G1/S Block
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stantiate these conclusions.
Materials and Methods
RNA Extraction and RT-PCR
Total RNA extraction from HeLa cell (ATCC CCL-2) lysates
was performed using TRIzol Reagent (Gibco BRL). The lysate
was mixed with 200 mL chloroform for 30 s at room temperature
(RT) for 3 min, centrifuged for 15 min at 12,000 g and 4uC. The
RNA is then precipitated from the aqueous phase in 500 mL
isopropanol. The RNA pellet was washed with 1 mL ethanol
75%, centrifuged for 5 min at 7,500 g and 4uC, dried and
resuspended in 10 mL of RNA-free water. The mRNA was
isolated by magnetic separation using Dynabeads Oligo (dT)
(Dynal) and reverse transcribed with Superscript Transcriptase
(Gibco BRL) and gene specific primer for Exon 8 of human
cyclin A2 (E8B: nt. 10102-10127, 59-TACTCAACACTTATA-
GAGGTTTGCTC-39). The cDNA was PCR amplified with
oligonucleotide primers designed for splice variant (A2V6) and
wild type of cyclin A2 (A2WT). Sense primer was located in
Exon 1 and anti-sense primer in Intron 6 or Exon 8. The primer
sequences were: sense primer, X1S (nt. 2972-2993, 59-
GGCGGCTACGACTATTCTTTGG-39); anti-sense primer,
A2I6B (nt. 7837-7860, 59-GCACAGGCATTTCAGTCACAA-
GAT-39); anti-sense primer, E8B. Five micrograms of cDNA
from cells and tissue panels (Clontech) were amplified using
Advantage cDNA polymerase kit (Clontech) for 35 cycles of
94uC for 30 s, 60uC for 90 s, and 72uC for 90 s.
Southern Hybridization
RT-PCR products separated on 1% agarose gel were trans-
ferred to a positively charged nylon membrane (GE Healthcare)
by the method of Southern. Oligonucleotide probes were labeled
with [
32P]dCTP using Megaprime DNA Labeling System (GE
Healthcare). Hybridization was performed in Church buffer [28].
Briefly, membranes were prehybridized for 1 hour at 65uC and
then hybridized in the same buffer with 1610
6 cpm/mL of
labeled probe overnight at 65uC. After hybridization, each filter
Figure 3. Overexpression of A2V6-GFP induces a G1/S arrest. HeLa cells were transfected with wild-type cyclin A2-GFP (A2WT-GFP) or Intron
6-retaining cyclin A2-GFP (A2V6-GFP) vectors. The analyses were performed in asynchronous cells (As), in thymidine-synchronized cells (0 h) and at
the indicated times (5.5 h, 10 h) after thymidine removal. (A) Anti-GFP immunoblot. The molecular mass of the GFP fusion proteins is 75–80 kDa.
Actin: normalization using b-actin. (B) Cell cycle analysis using flow cytometry. Inset: percentage of cells in the different phases of the cell cycle. NT:
non-transfected cells. Cells expressing A2V6-GFP were arrested in G1/S phase while cells expressing endogenous cyclin A2 or A2WT-GFP were
progressing through the cell cycle. (C) Anti-cyclin A2 immunoblot in lysates from cells expressing A2V6- and A2WT-GFP showing the expression of
endogenous cyclin A2 (single arrow) and the GFP fusion proteins (double arrow). Actin: normalization using b-actin. (D) Immunoblots for the CDK
inhibitors p21 and p27 in lysates from cells expressing A2V6- and A2WT-GFP demonstrating their accumulation in A2V6-GFP expressing cells (lane
5.5 h). NT: non-transfected cells. (E) Anti-total-retinoblastoma (Rb) and anti phospho-Rb immunoblots showing that phosphorylated Rb was present
in A2WT-GFP and non-transfected (NT) cell extracts, and not in A2V6-GFP cell extracts.
doi:10.1371/journal.pone.0039249.g003
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solution, and then exposed to X-ray film.
Plasmid Constructs
The PCR fragments X1S-A2I6B (A2V6) and X1S-E8B
(A2WT) were ligated in the pGEM-T cloning vector (Promega)
and the the JM109 competent bacteria were transformed.
Positive clones were selected by PCR with T7 primer and gene
specific human cyclin A2 primer X4R (nt. 6018–6042, 59-
CCACAAGCTGAAGTTTTCCTCTCAG-39) for 25 cycles of
94uC for 45 s, 60uC for 45 s, and 72uC for 45 s. The restriction
EcoRI/NotI fragment was separated on a 10% agarose gel,
purified by QIA quick gel purification kit (Qiagen) and inserted
into the pEGFP-C1 vector (Clontech) to create the pEGFP-A2V6
and pEGFP-A2WT vectors, and into pcDNA3.1/Myc-His
(Invitrogen) to create the pMyc-His-A2V6 and pMyc-His-
A2WT vectors.
Cell Culture, Transient Transfection, and Synchronization
HeLa cells were cultured in Dulbecco’s MEM with GlutaMAX
containing 10% fetal bovine serum (FBS) at 37uC and 5% CO2.
Cells grown on glass coverslip were transfected using ExGen 500
transfection reagent (Euromedex). Briefly, cells were plated at
1.5610
5 cells per well in 6-well plates. Twenty-four hours later,
1 mL of serum-free medium containing 8 mL of the ExGen 500
reagent and 2 mg of plasmid DNA was added to each well for
24 h. G1/S cell synchronization was done using double thymidine
block. The cells were treated with the 2 mM thymidine for 17 h
then changed to fresh medium for 9 h and replaced with 2 mM
thymidine medium for 15 h.
Immunofluorescence Confocal Microscopy and Time-
lapse Videomicroscopy
The transfected cells were fixed in 3% formaldehyde, rinsed and
permeabilized in phosphated-buffered saline (PBS) containing
0.2% Saponine. Fixed cells were incubated with the primary
antibodies for 45 min at RT and washed with PBS. They were
then incubated with Cy3- and Cy5-conjugated secondary anti-
bodies for 45 min at RT. Cell nuclei were stained with 49,6-
diamino-2-phenylindole (DAPI, Sigma). Sequential images were
taken at 0.4 mm intervals using a SP2 AOBS confocal microscope
(Leica). Time-lapse videomicroscopy was performed using a digital
microscope (Leica) equipped with a high-resolution CCD camera
(CoolSnap HQ, Photometrix) and a high-sensitivity camera
(Pentamax) driven by a Metamorph 6 software (Universal
Imaging).
Flow Cytometric Analysis
GFP-expressing cells were detached with trypsin-EDTA and
washed twice with ice-cold PBS, and 16110
6 cells were
resuspended in 500 mL of cold PBS. The cellular suspension was
mixed with 10 mg/mL Hoechst 33342 (1 mg/mL) and incubated
at 37uC for 45 min. Analysis by flow cytometry was performed
collecting 20,000 events per sample on a FACSCalibur flow
cytometer (BD Biosciences) using the CellQuest software (BD
Biosciences).
Immunoblotting and Immunoprecipitation
At 48 h post-transfection, total protein extracts were prepared
with a buffer containing 30 mM Tris HCl pH 7.5, 250 mM NaCl,
0.5% NP40, 1 mM sodium orthovanadate, 1 mM NaF and
protease inhibitors. For immunoprecipitation assays, cleared
lysates were incubated with anti-CDK2 antibody. Equal amounts
of extracts (40 mg) were separated on 8% SDS-PAGE, transferred
onto nitrocellulose (GE Healthcare) and processed for immuno-
blotting. Incubations were performed with a lysis buffer containing
20 mM Tris-HCl pH 7.5, 137 mM NaCl, 0.05% Tween 20 and
5% nonfat dry milk. The HRP-conjugated secondary antibodies
were used at a dilution of 1:2000 (GE Healthcare). The
chemoluminescence ECL Plus reagent was purchased from GE
Healthcare.
In vitro Kinase Reaction
Anti-GFP immunoprecipitates were washed three times with
kinase buffer (50 mM Tris HCl pH 7.5, 20 mM EGTA,
10 mM MgCl2, 1 mM DTT, 1mM b-glycerolphosphate), and
then incubated in 50 mL of kinase reaction buffer with 100 mM
cold ATP and 10 mCi [c-
32P]ATP for 30 min at 25uC. Samples
were analyzed by SDS-PAGE followed by autoradiography.
Antibodies
The antibodies used were: Mouse anti-c-Myc monoclonal
(9E10) and rabbit anti-CDK2 polyclonal (M2) antibodies (Santa
Cruz Biotechnology); Mouse anti-GFP monoclonal (JL-8) antibody
(Clontech); Mouse anti-human cyclin A2 monoclonal (11B2G3)
antibody (Immunotech); Rabbit anti-p21 polyclonal antibody
(Santa Cruz Biotechnology); Rabbit anti-p27 polyclonal antibody
(Santa Cruz Biotechnology); Rabbit anti-pRb polyclonal antibody
(Cell Signaling).
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Figure 4. A2V6-GFP binds CDK2 without inducing H1 kinase
activity. (A) Anti-GFP immunoblot (IB) from cell lysates immunopre-
cipitated (IP) with anti-CDK2 antibody. The A2V6-GFP fusion protein
(<75 kDa) interacts with CDK2 like the A2WT-GFP fusion protein
(<85 kDa). IgG: non-specific antibody control. (B) Autoradiography of
32P-labeled histone H1 performed after anti-GFP immunoprecipitation
in lysates from A2WT- and A2V6-GFP transfected cells. IgG: non-specific
antibody control. Input: non-immunoprecipitated lysate. No phosphor-
ylated histone H1 was detected in A2V6-GFP transfected cells,
indicating that the A2V6/CDK2 complexes, contrary to the A2WT/
CDK2 ones, are not functional. The phosphorylated histone H1 in the
input lanes corresponds to the global kinase activity of cycling
asynchronous cells.
doi:10.1371/journal.pone.0039249.g004
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